Generic Medicine Info
May be taken with or without food.
Concomitant use with aliskiren-containing products in patients with diabetes mellitus or renal impairment (GFR <60 mL/min). Severe hepatic impairment. Pregnancy (2nd-3rd trimester).
Special Precautions
Patient with history of angioedema, volume- and/or Na-depletion, heart failure, unstented unilateral/bilateral renal artery stenosis, aortic or mitral stenosis, cirrhosis. Black race. Renal impairment and mild to moderate hepatic impairment. Children and elderly. Lactation. Patient Counselling This drug may occasionally cause dizziness or drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Monitor blood pressure, renal function, and electrolytes level e.g. serum K, urininalysis. Correct volume depletion prior to therapy. Assess for signs of angioedema.
Adverse Reactions
Significant: Renal failure, renal insufficiency, symptomatic hypotension (in volume- or Na-depleted patients), hyperkalaemia, rarely, angioedema. Blood and lymphatic system disorders: Anaemia. Cardiac disorders: Chest pain, atrial fibrillation, palpitations, dyspnoea. Ear and labyrinth disorders: Tinnitus. Gastrointestinal disorders: Diarrhoea, constipation, nausea, vomiting. General disorders and administration site conditions: Asthenia, fatigue. Immune system disorders: Urticaria. Investigations: Increase in serum creatinine. Metabolism and nutrition disorders: Hypoglycaemia, oedema. Musculoskeletal and connective tissue disorders: Back pain, arthralgia, myalgia. Nervous system disorders: Dizziness, vertigo, headache, migraine, paraesthesia, cerebrovascular accident. Psychiatric disorders: Sleep disorder, depression. Renal and urinary disorders: UTI. Respiratory, thoracic and mediastinal disorders: Upper respiratory tract infection, nasal congestion, cough. Skin and subcutaneous tissue disorders: Pruritus, photosensitivity, rash. Vascular disorders: Orthostatic hypotension, syncope.
Drug Interactions
May potentiate hypotensive effect with other antihypertensive agents. May increase risk of hypotension as an adverse reaction of antipsychotics and amifostine. Decreased plasma concentration with rifampicin and fluconazole. Increased serum K levels and enhance hyperkalaemic effect with K-sparing diuretics (e.g. amiloride, spironolactone), K supplements or K-containing salt substitutes (e.g. heparin). May increase serum lithium concentrations and toxicity. May increase risk of renal impairment and may decrease hypotensive effect with NSAIDs.
ATC Classification
C09CA01 - losartan ; Belongs to the class of angiotensin II antagonists. Used in the treatment of cardiovascular disease.
Disclaimer: This information is independently developed by CIMS based on losartan from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in